CompletedNot Applicable

The Impact of Patch Rx Technologies on Adherence to Vitamin and Trikafta Therapies in Patients With Cystic Fibrosis

United States12 participantsStarted 2021-01-15

Plain-language summary

This proposed pilot study will assess if the Patch Technology system will increase adherence in patients with cystic fibrosis followed at the UTHSCSA Cystic Fibrosis Center.

Who can participate

Age range12 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Diagnosed with CF and cared for at University of Texas Health San Antonio Cystic Fibrosis clinic
✓. \> 12 years of age
✓. Prescribed a daily CF specific vitamin for at least 6 month
✓. Prescribed the genetic modulator elexacaftor/tezacaftor/ivacaftor for at least 6 month
✓. English speaking
✓. Patient possesses a Bluetooth enabled smartphone or mobile device.

What they're measuring

Adherence to Trikafta dosing

Timeframe: Baseline to 90 days

Adherence to Multivitamin dosing

Timeframe: Baseline to 90 days

Trial details

NCT IDNCT04684823

SponsorThe University of Texas Health Science Center at San Antonio

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-12-27

View on ClinicalTrials.gov More Cystic Fibrosis trials